The Cambridge ECMC aims to develop molecular prognostic and diagnostic tests to aid treatment decisions. The Centre focuses on genetic predisposition to cancer and the identification of high risk groups. This is being achieved by building on local strengths in genomics, pharmacogenetics, molecular pathology, molecular imaging, clinical informatics and computational biology.
The overall aim of the Cambridge ECMC is to deliver personliased cancer medicine as the means to better achieve cancer control as the means to better achieve cancer control. This personalistion of cancer medicine used the detailed characterisations of both the neoplasm and of the patient afflicated by it to improve screening, diagnosis, trageted treatment, and treatment monitoring.
Cancer control will be ultimately achieved through prevention, through early diagnosis, through better use of currently available treatments, and through the development of new better targeted therapeutics. The Cambridge ECMC provide support related to each of these areas.
As of 2017-2022 quinquennium, the Cambridge ECMC is also a member of the Paediatric Network.
In particular, the Cambridge ECMC will provide infrastructure support for 6 broad research areas:
Early-phase clinical trials and experimental therapeutics
Tumour monitoring (advanced cancer imaging)
Tumour monitoring (liquid biopsy, cf DNA)
Translational research in late-phase trials
Screening and intervention in high-risk groups
Organisations affiliated with the Cambridge ECMC:
Contact the Centre Manager: